Document Detail


Management of advanced stage uterine sarcomas: a bone of contention.
MedLine Citation:
PMID:  19899397     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Uterine sarcomas constitute a rare group of neoplasms characterized by an aggressive clinical course and poor prognosis. It is this rarity that has resulted in clinical-trial reports and literature reviews including a broad range of histological subtypes of sarcoma. This has a detrimental effect on interpretation and application of the results; the pathological subtype demands a tailored approach. Surgical resection remains the mainstay of treatment for non metastatic uterine sarcomas. Although adjuvant radiation therapy has reportedly been of little survival value, it appears to improve local control and may delay recurrence. The role of adjuvant chemotherapy has yet to be established; however, bearing in mind the limitations and assumptions in the pooling of data the therapeutic options should be based on the pathological subtype. Considering the poor overall survival in uterine sarcomas, the need for new therapeutic agents is critical. New drugs with possible activity in uterine sarcomas include trabectedin, temozolomide, liposomal doxorubicin and gemcitabine.
Authors:
F Zagouri; H Linardou; A M Dimopoulos; C A Papadimitriou
Related Documents :
22289277 - Response to sunitinib in combination with proton beam radiation in a patient with chond...
20716627 - Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analy...
22893727 - Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy.
22348437 - Incidence, risk factors and outcome of histological transformation in follicular lymphoma.
15291877 - Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node me...
12807227 - Reflections on the figo surgical staging of invasive epithelial ovarian cancer.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European journal of gynaecological oncology     Volume:  30     ISSN:  0392-2936     ISO Abbreviation:  Eur. J. Gynaecol. Oncol.     Publication Date:  2009  
Date Detail:
Created Date:  2009-11-10     Completed Date:  2009-12-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8100357     Medline TA:  Eur J Gynaecol Oncol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  483-92     Citation Subset:  IM    
Affiliation:
Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chemotherapy, Adjuvant
Female
Humans
Hysterectomy
Neoplasm Staging
Radiotherapy, Adjuvant
Sarcoma / pathology*,  therapy*
Tumor Markers, Biological
Uterine Neoplasms / pathology*,  therapy*
Chemical
Reg. No./Substance:
0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diagnosis and treatment of borderline ovarian neoplasms "the state of the art".
Next Document:  Patterns of care for the initial management of cervical cancer in Ontario.